(AAPL) Apple has 6 more days to reach an agreement with Cisco over the iPhone trademark.
(ADM) Archer Daniels Midland priced $1.15B in notes and will repurchase more than $350M in common stock.
(AMR) AMR up 9% pre-market after Business Week noted it could be acquired for $46 to $52; Reuters reports that British Air and Goldman Sachs are not planning to bid.
(BPT) Prudhoe Bay noted as a SELL on Cramer’s MAD MONEY.
(BUCY) Bucyrus reports this morning.
(CAE) Cascade will replace ELK in the S&P Small Cap 600 Index.
(CBSS) COMPASS BANK UP 7% AFTER BEING ACQUIRED BY BBVA in Spain.
(CECO) Career Education trading down 12% after earnings yesterday.
(CPB) Campbell soup reports this morning.
(CMG) Chipotle traded up 4% after beating earnings.
(CPKI) California Pizza Kitchen $0.19 EPS vs $0.16e.
(DRTE) Dendrite posted a loss buyt reaffirmed 2007 targets.
(EL) Estee Lauder approved a 20M share buyback plan.
(FPIC)) FPIC INSURANCE reports this morning.
(FRO) Frontline noted as a SELL on Cramer’s MAD MONEY.
(FRNT) Frontier Airlines announced pilots agreed to new contract.
(GOOG) Google bought private Adscape for video game advertising for $23 million according to Red Herring.
(GT) Goodyear Tire reports this morning.
(HON) Honeywell announced a $3 Billion stock buyback plan, close to 8% of the stock.
(HRL) Hormel $0.57 EPS vs $0.58e.
(ICGE) INternet Capital reports this morning.
(ISV) Inspire wins 413M payment in pact with Insite Vision plus $19M milestone.
(KNDL) Kendle $0.18 EPS vs $0.17e.
(LMS) Lamson & Sessions reports this morning.
(LOOK) Looksmart traded down 1.5% after beating EPS targets, but missed revenues and guided revenues down.
(MSFT) Microsoft trading down 1.4% after Ballmer noted some analyst expectations were too high for Vista at analyst meeting.
(MYL) Mylan Labs announced final FDA approval for propranolol hydrochloride extended-release capsules.
(NABI ) Nabi Bio chairman resigned.
(SJM) JM Smucker $0.72 EPS vs $0.69e.
(SMDI) Sirenza Micro founder and wife are selling 7M shares of common stock.
(SPPI) Spectrum Pharmaceuticals announces completion of NDA filing for satraplatin for hormone refractory prostate cancer
(VC) Visteon reported -$0.31 EPS but had huge gains and huge charges; estimates were -$0.80; sees challenges continuing.
(WYE) Wyeth announced that a Federal Jury rules for Wyeth in hormone replacement trial.